InSite's AzaSite royalties from Merck help avoid debt default
This article was originally published in Scrip
Executive Summary
InSite Vision has renegotiated its licence agreement with Merck & Co so that the Alameda, California-based company receives minimum royalty payments for AzaSite (azithromycin ophthalmic solution) 1% from its big pharma partner on a quarterly rather than yearly basis to avoid defaulting on its $60 million debt secured by AzaSite royalties.